Diabetes Complications

Metabolic Diseases
6
Pipeline Programs
5
Companies
4
Clinical Trials
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
1
0
3
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
267%
Monoclonal Antibody
133%
+ 1 programs with unclassified modality

On Market (2)

Approved therapies currently available

Novo Nordisk
SAXENDAApproved
liraglutide
Novo Nordisk
GLP-1 Receptor Agonist [EPC]subcutaneous2014
Novo Nordisk
VICTOZAApproved
liraglutide
Novo Nordisk
GLP-1 Receptor Agonist [EPC]subcutaneous2010

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
1 program
1
LiraglutidePhase 4Peptide1 trial
Active Trials
NCT02473809Completed60Est. Oct 2017
Novartis
NovartisBASEL, Switzerland
1 program
1
RanibizumabPhase 2/3Monoclonal Antibody1 trial
Active Trials
NCT01030770Completed25Est. May 2016
Grifols
GrifolsNEW YORK, NY
1 program
1
IGIV-CPhase 21 trial
Active Trials
NCT02915263TerminatedEst. Feb 2022
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
1
exenatidePhase 2Peptide1 trial
Active Trials
NCT00529204Terminated1Est. Feb 2010

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Novo NordiskLiraglutide
NovartisRanibizumab
GrifolsIGIV-C
Eli Lilly and Companyexenatide

Clinical Trials (4)

Total enrollment: 86 patients across 4 trials

NCT02473809Novo NordiskLiraglutide

The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell Function

Start: Aug 2015Est. completion: Oct 201760 patients
Phase 4Completed
NCT01030770NovartisRanibizumab

Preoperative Intravitreal Ranibizumab for Persistent Diabetic Vitreous Haemorrhage:

Start: Jul 2010Est. completion: May 201625 patients
Phase 2/3Completed
NCT02915263GrifolsIGIV-C

The Efficacy Of Intravenous Immunoglobulin Therapy In Treatment Induced Neuropathy Of Diabetes

Start: Sep 2017Est. completion: Feb 2022
Phase 2Terminated
NCT00529204Eli Lilly and Companyexenatide

Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver Disease

Start: Oct 2007Est. completion: Feb 20101 patients
Phase 2Terminated

Related Jobs in Metabolic Diseases

Manager, Patient Safety and Pharmacovigilance Operations

Kailera Therapeutics
Waltham, Massachusetts
8h ago

Senior Medical Science Liaison - Obesity - Northern CA, Central CA, NV

Amgen
California - San Francisco, US
Yesterday

(Sr) Scientist Analytical Chemistry – Mass Spectrometry (Temporary role 3 years)

Johnson & Johnson
Beerse, Antwerp, Belgium
2d ago

Computational Chemist

Topos Bio
San Francisco Office
2d ago

Associate Director, Legal Operations & Contracts Management

Kailera Therapeutics
Massachusetts
4d ago
From $155K/yr

Application & Integration Architect

Roche
Indianapolis
5d ago
$106K - $196K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

Peptide is the dominant modality (67% of programs)
5 companies competing in this space

Related Indications

Diabetes(737)Diabetes Mellitus, Type 2(485)Obesity(246)Type 2 Diabetes(207)Type 2 Diabetes Mellitus(190)Diabetes Mellitus(127)Diabetes Mellitus, Type 1(95)Type 1 Diabetes Mellitus(51)Type 1 Diabetes(50)Dyslipidemia(45)